Approaches to Foster Economic Sustainability of Precision Cancer Medicine and Cell Therapies
- Health Equity,
- Payment Models & Affordability
This project examines the high price effectiveness & value of precision cancer medicine and cell and gene therapies. The work to date has been widely disseminated to inform national policy discussions of the high price of cancer therapies, cell therapy and gene therapy.
This initiative examines the high price effectiveness and value of precision cancer medicine and cell and gene therapies. Projects have included a major symposium on cell and gene therapy, and deep dives into specific issues including policy proposals to address the high costs of cancer drugs and policy proposals to optimize payment for novel, impactful therapies, like CAR-T cell therapy.
The work to date has been widely disseminated to inform national policy discussions of the high price of cancer therapies, cell therapy and gene therapy.
Philanthropically funded Penn Gant Consortium Initiative; The New York Community Trust
Abramson Cancer Center Cancer Control Program; Radiation Oncology; Hematology and Oncology; Medical Ethics and Health Policy; The Wharton School; Leonard Davis Institute of Health Economics; The Center for Cell Therapy and Transplantation
Project Leads
Project Team
-
Abby Alpert
-
Christopher Manz
-
Dan Polsky
-
David Porter
